Principles underlying the use of conjunctive agents with plasminogen activators

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hematology

Background:

• Pharmacological thrombolysis involves concurrent fibrin degradation and procoagulant activity.
• Enhanced procoagulant and platelet activity can impede thrombolysis or cause reocclusion.
• Current treatments like heparin and aspirin have limitations in preventing thrombolysis complications.

Purpose of the Study:

• To evaluate the limitations of current pharmacological thrombolysis agents.
• To explore the potential of novel small molecule thrombin inhibitors and fibrinogen receptor antagonists.
• To suggest future clinical trial designs for improving thrombolysis efficacy.

Main Methods:

• Review of existing literature on pharmacological thrombolysis.
• Analysis of the mechanisms of action and limitations of heparin and aspirin.
• Discussion of the potential benefits of small molecule thrombin inhibitors and fibrinogen receptor antagonists.

Main Results:

• Heparin and aspirin are associated with a 10-20% complication rate during thrombolysis.
• Heparin's efficacy may be limited by the inaccessibility of the heparin-antithrombin III complex to fibrin-bound thrombin.
• Aspirin's antiplatelet effect is restricted to thromboxane-dependent aggregation.

Conclusions:

• Heparin and aspirin are not universally effective in preventing thrombolysis complications.
• Small molecule, active-site thrombin inhibitors may offer superior efficacy compared to heparin.
• Fibrinogen receptor antagonists provide broader platelet aggregation inhibition than aspirin.
• Future clinical trials should investigate thrombin inhibitors and fibrinogen receptor antagonists for improved thrombolysis outcomes.